This company has been marked as potentially delisted and may not be actively trading. Champions Oncology (CSBR) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock CSBR vs. VECT, SANA, RLAY, OPT, MAZE, CGEM, AUTL, TRML, DNA, and RGNXShould you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include VectivBio (VECT), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), Opthea (OPT), Maze Therapeutics (MAZE), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Tourmaline Bio (TRML), Ginkgo Bioworks (DNA), and REGENXBIO (RGNX). These companies are all part of the "biological products, except diagnostic" industry. Champions Oncology vs. VectivBio Sana Biotechnology Relay Therapeutics Opthea Maze Therapeutics Cullinan Therapeutics Autolus Therapeutics Tourmaline Bio Ginkgo Bioworks REGENXBIO VectivBio (NASDAQ:VECT) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings. Do insiders and institutionals hold more shares of VECT or CSBR? 41.3% of Champions Oncology shares are owned by institutional investors. 9.7% of VectivBio shares are owned by insiders. Comparatively, 47.0% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer VECT or CSBR? In the previous week, Champions Oncology had 3 more articles in the media than VectivBio. MarketBeat recorded 3 mentions for Champions Oncology and 0 mentions for VectivBio. Champions Oncology's average media sentiment score of 1.04 beat VectivBio's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the news media. Company Overall Sentiment VectivBio Neutral Champions Oncology Positive Does the MarketBeat Community prefer VECT or CSBR? Champions Oncology received 142 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 60.56% of users gave Champions Oncology an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformVectivBioOutperform Votes1043.48% Underperform Votes1356.52% Champions OncologyOutperform Votes15260.56% Underperform Votes9939.44% Do analysts prefer VECT or CSBR? Champions Oncology has a consensus price target of $12.00, indicating a potential upside of 44.40%. Given Champions Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Champions Oncology is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Champions Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, VECT or CSBR? VectivBio has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Which has preferable valuation & earnings, VECT or CSBR? Champions Oncology has higher revenue and earnings than VectivBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVectivBio$27.34M20.97-$93.74MN/AN/AChampions Oncology$50.15M2.29-$7.28M-$0.06-138.48 Is VECT or CSBR more profitable? VectivBio has a net margin of 0.00% compared to Champions Oncology's net margin of -1.12%. Company Net Margins Return on Equity Return on Assets VectivBioN/A N/A N/A Champions Oncology -1.12%N/A -2.32% SummaryChampions Oncology beats VectivBio on 12 of the 15 factors compared between the two stocks. Remove Ads Get Champions Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSBR vs. The Competition Export to ExcelMetricChampions OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.96M$2.97B$5.54B$7.49BDividend YieldN/A1.53%5.35%4.04%P/E Ratio-144.2330.4323.2518.07Price / Sales2.29383.26361.2686.80Price / CashN/A168.6838.1634.64Price / Book-59.363.646.493.99Net Income-$7.28M-$72.06M$3.21B$247.18M Champions Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSBRChampions Oncology3.5803 of 5 stars$8.31-14.1%$12.00+44.4%+70.7%$144.96M$50.15M-144.23143News CoveragePositive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeSANASana Biotechnology3.2444 of 5 stars$2.42+4.8%$10.80+346.3%-81.5%$544.56MN/A-1.73380Gap DownRLAYRelay Therapeutics2.18 of 5 stars$3.10+1.3%$19.80+538.7%-67.2%$525.52M$10.01M-1.19330Gap DownOPTOpthea0.8475 of 5 stars$3.41+7.2%$12.00+251.9%-13.7%$524.84M$87,666.000.008Short Interest ↑Gap UpMAZEMaze TherapeuticsN/A$11.86+6.5%$25.67+116.4%N/A$519.20M$167.50M0.00121Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCGEMCullinan Therapeutics2.098 of 5 stars$8.54+0.2%$32.86+284.7%-54.0%$499.70MN/A-3.0130News CoveragePositive NewsGap DownAUTLAutolus Therapeutics2.6598 of 5 stars$1.71+0.6%$9.52+456.7%-71.5%$455.02M$10.12M-1.41330Analyst ForecastGap DownTRMLTourmaline Bio1.791 of 5 stars$17.61+2.7%$50.00+183.9%-38.5%$452.31MN/A-6.2444Gap DownDNAGinkgo Bioworks0.5803 of 5 stars$7.68+5.7%$4.58-40.5%N/A$445.93M$227.04M-0.59640News CoverageGap DownRGNXREGENXBIO4.5211 of 5 stars$8.70+5.6%$33.88+289.4%-65.3%$435.75M$83.33M-1.73370Gap Down Remove Ads Related Companies and Tools Related Companies VECT Competitors SANA Competitors RLAY Competitors OPT Competitors MAZE Competitors CGEM Competitors AUTL Competitors TRML Competitors DNA Competitors RGNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSBR) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
